These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Healthcare resource use and costs of diabetic macular oedema for patients with antivascular endothelial growth factor versus a dexamethasone intravitreal implant in Korea: a population-based study. Cho H; Choi KS; Lee JY; Lee D; Choi NK; Lee Y; Bae S BMJ Open; 2019 Sep; 9(9):e030930. PubMed ID: 31542758 [TBL] [Abstract][Full Text] [Related]
11. Comparative effectiveness and harms of intravitreal antivascular endothelial growth factor agents for three retinal conditions: a systematic review and meta-analysis. Low A; Faridi A; Bhavsar KV; Cockerham GC; Freeman M; Fu R; Paynter R; Kondo K; Kansagara D Br J Ophthalmol; 2019 Apr; 103(4):442-451. PubMed ID: 30409915 [TBL] [Abstract][Full Text] [Related]
12. Comparison between Ozurdex and intravitreal anti-vascular endothelial growth factor treatment for retinal vein occlusion-related macular edema: A systematic review and meta-analysis of randomized controlled trials. Hu Q; Li H; Xu W; Du Y; Ma C; He J Indian J Ophthalmol; 2019 Nov; 67(11):1800-1809. PubMed ID: 31638037 [TBL] [Abstract][Full Text] [Related]
13. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Heier JS; Campochiaro PA; Yau L; Li Z; Saroj N; Rubio RG; Lai P Ophthalmology; 2012 Apr; 119(4):802-9. PubMed ID: 22301066 [TBL] [Abstract][Full Text] [Related]
14. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema. Callanan DG; Loewenstein A; Patel SS; Massin P; Corcóstegui B; Li XY; Jiao J; Hashad Y; Whitcup SM Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):463-473. PubMed ID: 27632215 [TBL] [Abstract][Full Text] [Related]
15. Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema. Fong AH; Lai TY Clin Interv Aging; 2013; 8():467-83. PubMed ID: 23766636 [TBL] [Abstract][Full Text] [Related]
16. Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNV. Wecker T; Ehlken C; Bühler A; Lange C; Agostini H; Böhringer D; Stahl A Br J Ophthalmol; 2017 Mar; 101(3):353-359. PubMed ID: 27215744 [TBL] [Abstract][Full Text] [Related]
17. Ranibizumab and retinal vein occlusion. Too many outstanding questions. Prescrire Int; 2012 Sep; 21(130):207. PubMed ID: 23016250 [TBL] [Abstract][Full Text] [Related]
18. Trends of Anti-Vascular Endothelial Growth Factor Use in Ophthalmology Among Privately Insured and Medicare Advantage Patients. Parikh R; Ross JS; Sangaralingham LR; Adelman RA; Shah ND; Barkmeier AJ Ophthalmology; 2017 Mar; 124(3):352-358. PubMed ID: 27890437 [TBL] [Abstract][Full Text] [Related]
19. Intravitreal Dexamethasone Implant versus Intravitreal Ranibizumab for the Treatment of Macular Edema Secondary to Retinal Vein Occlusion in a Chinese Population. Gu X; Yu X; Song S; Dai H Ophthalmic Res; 2017; 58(1):8-14. PubMed ID: 28334720 [TBL] [Abstract][Full Text] [Related]
20. Critical appraisal of ranibizumab in the treatment of diabetic macular edema. Stewart MW Clin Ophthalmol; 2013; 7():1257-67. PubMed ID: 23836955 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]